← All trials
NCT05338619
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Mar 2, 2026
- Completion date
- Mar 2, 2026
- First posted
- Apr 21, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 77
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Korea UniversityLead sponsor
- Korea UniversityOverall official - principal investigator
- Korea UniversitySponsor investigator
- Yuhan Pharmaceutical CompanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.